Raghava N Sriramaneni Selected Research

Raghava N Sriramaneni Research Topics

15	Neoplasms (Cancer) 01/2023 - 01/2018
3	Melanoma (Melanoma, Malignant) 01/2021 - 01/2017
2	Inflammation (Inflammations) 01/2023 - 11/2018
2	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2021
2	Brain Neoplasms (Brain Tumor) 01/2021 - 01/2020
1	Breast Neoplasms (Breast Cancer) 01/2023
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021
1	Bites and Stings (Sting) 01/2021
1	Squamous Cell Carcinoma of Head and Neck 01/2020
1	Thrombocytopenia (Thrombopenia) 06/2014
1	Rheumatoid Arthritis 06/2014
1	Edema (Dropsy) 06/2014

8	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2020
7	CytokinesIBA 01/2023 - 01/2018
6	Interleukin-2 (IL2)IBA 01/2023 - 01/2018
3	VaccinesIBA 01/2023 - 01/2020
3	Radioisotopes (Radionuclides)IBA 01/2021 - 01/2021
3	LigandsIBA 01/2020 - 01/2017
2	Immunoglobulin G (IgG)IBA 01/2020 - 01/2018
1	Estrogen ReceptorsIBA 01/2023
1	Fulvestrant (Faslodex)FDA Link 01/2023
1	Estrogens (Estrogen)FDA Link 01/2023
1	Lysine (L-Lysine)FDA Link 01/2023
1	ferric oxide (iron oxide)IBA 01/2023
1	AntibodiesIBA 10/2022
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2022
1	Iohexol (Omnipaque)FDA Link 07/2021
1	bempegaldesleukinIBA 01/2021
1	Yttrium-86IBA 01/2021
1	ChemokinesIBA 01/2021
1	Interleukin-10 (Interleukin 10)IBA 01/2021
1	Interleukin-13IBA 01/2021
1	InterferonsIBA 01/2021
1	Neoplasm AntibodiesIBA 01/2020
1	Interferon Type IIBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Cetuximab (Erbitux)FDA Link 01/2020
1	AntigensIBA 11/2018
1	Therapeutic UsesIBA 01/2018
1	Death Domain ReceptorsIBA 01/2017
1	nimesulide (Aulin)IBA 06/2014
1	CarrageenanIBA 06/2014

10	Radiotherapy 01/2023 - 11/2018
8	Immunotherapy 01/2023 - 11/2018
7	Therapeutics 01/2023 - 01/2018
3	Brachytherapy 07/2021 - 11/2018
1	Tattooing 07/2021
1	Drug Therapy (Chemotherapy) 07/2021
1	Cell- and Tissue-Based Therapy (Cell Therapy) 07/2021
1	Oral Administration 06/2014